1. Home
  2. ENTA vs PACK Comparison

ENTA vs PACK Comparison

Compare ENTA & PACK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.43

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

HOLD

Current Price

$3.86

Market Cap

303.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
PACK
Founded
1995
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Containers/Packaging
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
303.3M
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
ENTA
PACK
Price
$14.43
$3.86
Analyst Decision
Strong Buy
Buy
Analyst Count
5
3
Target Price
$20.40
$6.50
AVG Volume (30 Days)
111.5K
332.3K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
$395,000,000.00
Revenue This Year
$7.76
$9.29
Revenue Next Year
N/A
$8.35
P/E Ratio
N/A
N/A
Revenue Growth
16.48
7.08
52 Week Low
$4.83
$2.91
52 Week High
$17.15
$6.31

Technical Indicators

Market Signals
Indicator
ENTA
PACK
Relative Strength Index (RSI) 63.71 50.54
Support Level $13.39 $3.36
Resistance Level $15.52 $5.78
Average True Range (ATR) 0.82 0.16
MACD 0.24 0.09
Stochastic Oscillator 87.90 89.72

Price Performance

Historical Comparison
ENTA
PACK

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

Share on Social Networks: